OP 3136
Alternative Names: OP-3136Latest Information Update: 06 May 2025
At a glance
- Originator Olema Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KAT6A protein inhibitors; KAT6B protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 positive breast cancer; Non-small cell lung cancer; Prostate cancer
- Preclinical Ovarian cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical trial in Non-small cell lung cancer, Prostate cancer and Ovarian cancer released by Olema Pharmaceuticals
- 25 Mar 2025 Preclinical trials in Ovarian cancer in USA (PO)
- 16 Dec 2024 Phase-I clinical trials in HER2-positive-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06784193)